"I don't think that the regulatory standards are inconsistent or too hard. The FDA and EMA are just trying to come up with a quality threshold that will actually, in the end, facilitate these medicines."
Geoff MacKay, president and CEO of Avrobio Inc., discussing the regulatory path that requires manufacturing consistency for cell and gene therapy

"It's unfortunate for Seres that they suffered a setback, but I don't think that's going to affect all the rest of us who have worked to bring this [kind of] therapy forward. But time will tell, and our clinical trials will also show that. [Microbiome research] is going to continue to grow fast. People are experimenting with microbes because they're pretty readily available. I don't think the momentum is going to stop."
Lee Jones, CEO, Rebiotix Inc., on Seres Therapeutics Inc.'s failed microbiome phase II study with SER-109 against recurrent Clostridium difficile infection

"Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body's organs, which may become distorted in many chronic diseases."
Moncef Slaoui, chairman of global vaccines, Glaxosmithkline plc (GSK), on the rationale to evaluate bioelectronics medicine to combat chronic conditions with Google's parent company, Alphabet Inc.